var data={"title":"Bacitracin, neomycin, polymyxin B, and hydrocortisone (ophthalmic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bacitracin, neomycin, polymyxin B, and hydrocortisone (ophthalmic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/770537?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bacitracin-neomycin-polymyxin-b-and-hydrocortisone-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bacitracin, neomycin, polymyxin B, and hydrocortisone (ophthalmic): Patient drug information&quot;</a> and <a href=\"topic.htm?path=bacitracin-neomycin-polymyxin-b-and-hydrocortisone-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bacitracin, neomycin, polymyxin B, and hydrocortisone (ophthalmic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407050\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Neo-Polycin HC</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407055\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Ophthalmic;</li>\n      <li>\n        Corticosteroid, Ophthalmic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407084\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Inflammatory ocular conditions:</b> Ophthalmic: Apply to inside of lower lid of affected eye(s) every 3 or 4 hours (depending on severity of condition)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407085\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407086\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407087\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407098\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neo-Polycin HC: Bacitracin 400 units, neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per g (3.5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: Bacitracin 400 units, neomycin 3.5 mg, polymyxin B 10,000 units, and hydrocortisone 10 mg per g (3.5 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407053\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407088\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Ophthalmic: For topical ophthalmic use only; apply directly into conjunctival sac. To avoid contamination, do not touch tube tip to eyelids or other surfaces when placing ointment in eye(s).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407058\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Inflammatory ocular conditions:</b> Corticosteroid-responsive inflammatory ocular conditions where bacterial infection or risk of bacterial infection exists</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407066\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407063\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Hypersensitivity to bacitracin, neomycin, polymyxin B, hydrocortisone, or any component of the formulation; most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella; mycobacterial ophthalmic infection; fungal diseases of ocular structures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407064\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infection: Steroids may mask infection, enhance existing ocular infection, or reactivate latent disease (eg, herpes infection of cornea); prolonged use may result in secondary bacterial or fungal superinfection due to immunosuppression. Lack of prompt clinical response may indicate resistance to therapy and warrant discontinuation of therapy and further evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neomycin sensitization: Neomycin may cause cutaneous sensitization. Symptoms of neomycin sensitization include itching, reddening, edema, and failure to heal. Discontinuation of product and avoidance of similar products should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular effects: Avoid prolonged use of corticosteroids, which may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Use with caution in glaucoma. Monitor intraocular pressure (routinely if duration of therapy is &gt;10 days). Long-term use may cause corneal and scleral thinning; potentially resulting in perforation. Ophthalmic ointments may retard corneal wound healing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For topical use only. Do not inject subconjunctivally or introduce directly into anterior chamber of the eye. Use following ocular cataract surgery may delay healing and increase the incidence of filtering blebs. Inadvertent contamination of multiple-dose ophthalmic tube tip has caused bacterial keratitis. Use of topical corticosteroids to prevent scarring in the healing stages of herpes simplex infection should be done with extreme caution and close observation; may reactivate disease. A maximum of 8 g should be prescribed initially; reevaluate patients (eg, intraocular pressure and exams using magnification and fluorescein staining, where appropriate) prior to additional refills. Use &gt;10 days should include routine monitoring of intraocular pressure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407073\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407070\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=104674&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407059\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407060\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with topical corticosteroids in animal reproduction studies. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples, 1988). Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407061\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if systemic absorption following topical administration results in detectable quantities in human milk. The manufacturers recommend a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407091\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">If ophthalmic ointment is used &gt;10 days or in patients with glaucoma, monitor intraocular pressure (IOP).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407078\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407080\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407101\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Neo-Polycin HC Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (3.5 g): $59.98</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo; <i>J Natl Cancer Inst</i>, 2002, 94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bacitracin-neomycin-polymyxin-b-and-hydrocortisone-ophthalmic-drug-information/abstract-text/12441327/pubmed\" target=\"_blank\" id=\"12441327\">12441327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone [prescribing information]. Tampa, FL: Bausch amp Lomb Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone [prescribing information]. Lake Forest, IL: Akorn Inc; October 2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neo-Polycin HC (neomycin and polymyxin B sulfates, bacitracin zinc, and hydrocortisone) [prescribing information]. Locust Valley, NY: Fera Pharmaceuticals LLC; March 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bacitracin-neomycin-polymyxin-b-and-hydrocortisone-ophthalmic-drug-information/abstract-text/2903673/pubmed\" target=\"_blank\" id=\"2903673\">2903673</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 104674 Version 18.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28407050\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28407055\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28407084\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28407085\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28407086\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28407087\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28407098\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F28407053\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28407088\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28407058\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28407066\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28407063\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28407064\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28407073\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28407070\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28407059\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28407060\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28407061\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28407091\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28407078\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F28407080\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28407101\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/104674|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bacitracin-neomycin-polymyxin-b-and-hydrocortisone-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Bacitracin, neomycin, polymyxin B, and hydrocortisone (ophthalmic): Patient drug information</a></li><li><a href=\"topic.htm?path=bacitracin-neomycin-polymyxin-b-and-hydrocortisone-ophthalmic-pediatric-drug-information\" class=\"drug drug_pediatric\">Bacitracin, neomycin, polymyxin B, and hydrocortisone (ophthalmic): Pediatric drug information</a></li></ul></div></div>","javascript":null}